Exhibit 99(a)(15)

Press Release

            IVAX REPORTS PROGRESS IN TENDER OFFER FOR LABORATORIO
             CHILE S.A.; DUE DILIGENCE CONDITION SATISFIED; OTHER
         CONDITIONS REMAIN, INCLUDING 67% OF SHARES MUST BE TENDERED
                     BEFORE SHAREHOLDERS MEETING TOMORROW

     MIAMI--June 21, 2001-- IVAX (AMEX:IVX- news) said today progress has been
made on its pending tender offer in the United States (the "U.S. Offer") and the
pending tender offer in Chile (the "Chilean Offer") for all of the outstanding
shares and American Depositary Shares (ADSs) of Laboratorio Chile S.A. IVAX
announced that it had completed its due diligence review of Laboratorio Chile,
and as a result of such review, the due diligence condition set forth in Section
15(d) of the U.S. Offer to Purchase and Section 7 (b)4 of the Chilean prospectus
has been satisfied.

     IVAX cautions that other important conditions to the offer remain,
including that at least 67% of the outstanding Shares (including Shares
represented by the ADSs) shall have been tendered into the offer before the
Company's Shareholders Meeting, which has been scheduled for 4:00 PM, June 22,
2001. Therefore, IVAX strongly encourages all holders of Shares and/or ADSs to
instruct their bank or broker to tender their Shares and/or ADSs as soon as
possible.

     Except for the due diligence condition, which has been satisfied, the terms
and conditions of IVAX' U.S. Offer and concurrent Chilean Offer remain in effect
and unmodified.

     IVAX Corporation, headquartered in Miami, Florida, is engaged in the
research, development, manufacturing, and marketing of branded and brand
equivalent pharmaceuticals and veterinary and diagnostic products in the U.S.
and international markets.

     Except for the historical matters contained herein, statements in this
press release are forward-looking. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect IVAX' business and
prospects, including the risks that the remaining conditions for the successful
completion of the tender offer for Laboratorio Chile may not be satisfied; that
upon completion of the tender offer IVAX may not be able to integrate the
operations of Laboratorio Chile without significant capital expenditures or
other costs; that IVAX may not realize the anticipated benefits of the
acquisition of Laboratorio Chile; that if the tender offer is completed that
risks will arise from the operation of Laboratorio Chile; and other factors
discussed in the Company's Annual Report on form 10K and other filings with the
Securities and Exchange Commission.


CONTACT:

IVAX Corporation, Miami
Investor Relations
Tabitha H. Licea, 305/575-6043
www.ivax.com